AI drug discovery startup Basecamp Research raises $140M
The Series C funding round accelerates the development of generative AI models for novel protein design.
Basecamp Research Ltd. today announced that it has raised $140 million in funding from a group of prominent investors. S32, a fund affiliated with Google LLC co-founder Bill Maris, led the Series C round. It was joined by more than a dozen other investors. The group included NATO...
SiliconANGLE
Source
Generated insight by OnAirToday AI
Basecamp Research is revolutionizing drug discovery by utilizing massive, proprietary protein datasets to train AI models that predict complex biological interactions. This significant capital injection underscores the growing shift toward data-centric AI approaches capable of accelerating pharmaceutical breakthroughs far beyond traditional R&D speeds.
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.